Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals and Novavax Shares Are Exploding Higher Today

By George Budwell – Updated Feb 24, 2020 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The COVID-19 respiratory disease is quickly morphing into a pandemic.

What happened

Shares of the clinical-stage vaccine companies Inovio Pharmaceuticals (INO 2.68%) and Novavax (NVAX -1.99%) both jumped by as much as 18% in pre-market trading Monday morning. Inovio and Novavax appear to be getting a major boost this morning from the latest COVID-19 statistics, which seem to indicate that the outbreak is quickly turning into a global pandemic. 

The biggest takeaway is that Iran, Italy, and South Korea all saw a sharp rise in the number of COVID-19 cases over the weekend. Afghanistan, Egypt, and Lebanon also reported their first COVID-19 infections recently, indicating that the virus is starting to spread across the globe.  

A vial of blood labeled positive for coronavirus.

Image source: Getty Images.

So what

Investors are clearly banking on Inovio or Novavax being among the first companies to develop an effective vaccine against this deadly respiratory virus. Inovio, for its part, previously announced that it has an experimental vaccine already designed and ready for human trials. Novavax hasn't said much about its COVID-19 prospect, but it also stated near the beginning of the outbreak that it had a promising vaccine in the works as well. Both companies noted that they could kick off clinical trials for their respective COVID-19 vaccine candidates within just a matter of months. 

Now what

Is this viral outbreak a compelling buying opportunity? In short, there's no logical reason to buy either of these developmental biotech stocks on this news. Any experimental vaccine will likely take years to trial and subsequently gain marketing approval. By then, the COVID-19 threat will most likely have petered out.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.20 (-1.99%) $0.37
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (2.68%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.